Literature DB >> 22016143

Implications for cancer genetics practice of pro-actively assessing family history in a General Practice cohort in North West London.

Kelly Kohut1, Lucia D'Mello, Elizabeth K Bancroft, Sarah Thomas, Mary-Anne Young, Kathryn Myhill, Susan Shanley, Brian H J Briggs, Michelle Newman, Ifthikhar M Saraf, Penny Cox, Sarah Scambler, Lyndon Wagman, Michael T Wyndham, Rosalind A Eeles, Michelle Ferris.   

Abstract

At present cancer genetics referrals are reactive to individuals asking for a referral and providing a family history thereafter. A previous pilot study in a single General Practice (GP) catchment area in North London showed a 1.5-fold increase in breast cancer risk in the Ashkenazi Jewish population compared with the non-Ashkenazi mixed population. The breast cancer incidence was equal in the Ashkenazim in both pre- and postmenopausal groups. We wanted to investigate the effect of proactively seeking family history data from the entire female population of the practice to determine the effect on cancer genetics referral. Objectives To determine the need for cancer genetics intervention for women in a single GP catchment area. (1) to determine the incidence and strength of family history of cancer in women aged over 18 in the practice, (2) to offer cancer genetics advice and determine the uptake of counselling in those with a positive family history, (3) to identify potential BRCA1/BRCA2 gene mutation carriers who can be offered clinical follow up with appropriate translational research studies. Design Population-based cohort study of one General Practice female population. Participants Three hundred and eighty-three women over the age of 18 from one General Practice who responded to a questionnaire about family history of cancer. The whole female adult GP population was the target and the total number sampled was 3,820. Results 10% of patients completed the questionnaire (n = 383). A family history of cancer was present in 338 cases, 95 went on to have genetic counselling or had previously had counselling and 47 were genetically tested. We identified three carriers of an Ashkenazi Jewish founder mutation in BRCA1. Conclusions Response rate to a family history questionnaire such as that used in genetics centres was low (10%) and other approaches will be needed to proactively assess family history. Although the Ashkenazim are present in 39% of the GP catchment area, 62% of those who returned a family history questionnaire were from this ethnic group and of those returned, 44% warranted referral to a cancer genetics unit. In the non Ashkenazim, the questionnaire return rate was 38% and 18% of those warranted referral to cancer genetics.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22016143     DOI: 10.1007/s10689-011-9482-6

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  12 in total

Review 1.  Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families.

Authors:  P Tonin; B Weber; K Offit; F Couch; T R Rebbeck; S Neuhausen; A K Godwin; M Daly; J Wagner-Costalos; D Berman; G Grana; E Fox; M F Kane; R D Kolodner; M Krainer; D A Haber; J P Struewing; E Warner; B Rosen; C Lerman; B Peshkin; L Norton; O Serova; W D Foulkes; J E Garber
Journal:  Nat Med       Date:  1996-11       Impact factor: 53.440

2.  The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews.

Authors:  P Hartge; J P Struewing; S Wacholder; L C Brody; M A Tucker
Journal:  Am J Hum Genet       Date:  1999-04       Impact factor: 11.025

3.  The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.

Authors:  J P Struewing; P Hartge; S Wacholder; S M Baker; M Berlin; M McAdams; M M Timmerman; L C Brody; M A Tucker
Journal:  N Engl J Med       Date:  1997-05-15       Impact factor: 91.245

4.  Cancer risks in BRCA2 mutation carriers.

Authors: 
Journal:  J Natl Cancer Inst       Date:  1999-08-04       Impact factor: 13.506

5.  Effect of prevention strategies on survival and quality-adjusted survival of women with BRCA1/2 mutations: an updated decision analysis.

Authors:  Victor R Grann; Judith S Jacobson; Dustin Thomason; Dawn Hershman; Daniel F Heitjan; Alfred I Neugut
Journal:  J Clin Oncol       Date:  2002-05-15       Impact factor: 44.544

6.  Variation in cancer risks, by mutation position, in BRCA2 mutation carriers.

Authors:  D Thompson; D Easton
Journal:  Am J Hum Genet       Date:  2001-01-19       Impact factor: 11.025

7.  Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women.

Authors:  Kelly A Metcalfe; Aletta Poll; Robert Royer; Marcia Llacuachaqui; Anna Tulman; Ping Sun; Steven A Narod
Journal:  J Clin Oncol       Date:  2009-12-14       Impact factor: 44.544

8.  Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study.

Authors:  Susan M Domchek; Tara M Friebel; Susan L Neuhausen; Theresa Wagner; Gareth Evans; Claudine Isaacs; Judy E Garber; Mary B Daly; Rosalind Eeles; Ellen Matloff; Gail E Tomlinson; Laura Van't Veer; Henry T Lynch; Olufunmilayo I Olopade; Barbara L Weber; Timothy R Rebbeck
Journal:  Lancet Oncol       Date:  2006-03       Impact factor: 41.316

9.  Cost-effectiveness of population-based BRCA1/2 testing and ovarian cancer prevention for Ashkenazi Jews: a call for dialogue.

Authors:  Wendy S Rubinstein; Hongmei Jiang; Lisa Dellefave; Alfred W Rademaker
Journal:  Genet Med       Date:  2009-09       Impact factor: 8.822

10.  A population-based audit of ethnicity and breast cancer risk in one general practice catchment area in North London, UK: implications for practice.

Authors:  Michelle Ferris; Douglas F Easton; Rebecca J Doherty; Brian Hj Briggs; Michelle Newman; Ifthikhar M Saraf; Sarah Scambler; Lyndon Wagman; Michael T Wyndham; Ann Ward; Rosalind A Eeles
Journal:  Hered Cancer Clin Pract       Date:  2007-09-15       Impact factor: 2.857

View more
  3 in total

1.  All in the Family: Barriers and Motivators to the Use of Cancer Family History Questionnaires and the Impact on Attendance Rates.

Authors:  Susan Randall Armel; Jeanna McCuaig; Nicole Gojska; Rochelle Demsky; Manjula Maganti; Joan Murphy; Barry Rosen
Journal:  J Genet Couns       Date:  2015-01-07       Impact factor: 2.537

2.  A primary care audit of familial risk in patients with a personal history of breast cancer.

Authors:  Paul Nathan; Aneeta Ahluwalia; Wendy Chorley
Journal:  Fam Cancer       Date:  2014-12       Impact factor: 2.375

3.  Analysis of patient reports on the referral process to two NSW cancer genetic services.

Authors:  Grace I Butel-Simoes; Allan D Spigelman
Journal:  Fam Cancer       Date:  2014-09       Impact factor: 2.375

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.